Imunon’s (IMNN) Buy Rating Reiterated at D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $29.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the company. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a report on Monday, September 23rd. HC Wainwright lowered their price target on shares of Imunon from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, November 11th.

Imunon Stock Performance

NASDAQ IMNN opened at $0.85 on Tuesday. The firm has a market capitalization of $12.37 million, a P/E ratio of -0.45 and a beta of 2.12. Imunon has a fifty-two week low of $0.48 and a fifty-two week high of $3.65. The stock has a 50-day simple moving average of $0.90 and a two-hundred day simple moving average of $1.11.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.